Publikationer av Anna Månberg
Refereegranskade
Artiklar
[1]
S. Mravinacová et al., "CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration," Molecular Neurodegeneration, vol. 19, no. 1, 2024.
[2]
F. Bradley et al., "Estradiol-mediated enhancement of the human ectocervical epithelial barrier correlates with desmoglein-1 expression in the follicular menstrual phase," Frontiers in Endocrinology, vol. 15, 2024.
[3]
A. Jernbom Falk et al., "Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19," Nature Communications, vol. 15, no. 1, 2024.
[4]
A. Ullgren et al., "Altered plasma protein profiles in genetic FTD : a GENFI study," Molecular Neurodegeneration, vol. 18, no. 1, 2023.
[5]
J. Olofsson et al., "Array-Based Multiplex and High-Throughput Serology Assays," Methods in Molecular Biology, vol. 2628, s. 535-553, 2023.
[6]
G. Edfeldt et al., "Distinct cervical tissue-adherent and luminal microbiome communities correlate with mucosal host gene expression and protein levels in Kenyan sex workers," Microbiome, vol. 11, no. 1, 2023.
[7]
C. E. Teunissen et al., "Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias," Molecular & Cellular Proteomics, vol. 22, no. 10, 2023.
[8]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, s. 46-52, 2022.
[9]
U. Kläppe et al., "Cardiac troponin T is elevated and increases longitudinally in ALS patients," Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 23, no. 1-2, s. 58-65, 2022.
[10]
I. Lauren et al., "Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology," Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.
[11]
F. Bradley et al., "Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate," PLoS Pathogens, vol. 18, no. 5, 2022.
[12]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, s. 72-80, 2022.
[13]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, s. e0262169-e0262169, 2022.
[14]
A. Månberg et al., "Altered perivascular fibroblast activity precedes ALS disease onset," Nature Medicine, vol. 27, no. 4, 2021.
[15]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.
[16]
J. Remnestål et al., "Association of CSF proteins with tau and amyloid beta levels in asymptomatic 70-year-olds," Alzheimer's Research & Therapy, vol. 13, no. 1, 2021.
[17]
D. Just et al., "Autoantibodies against the C-terminus of Lipopolysaccharide binding protein are elevated in young adults with psychiatric disease," Psychoneuroendocrinology, vol. 126, 2021.
[18]
A. Jernbom Falk et al., "Autoantibody profiles associated with clinical features in psychotic disorders," Translational Psychiatry, vol. 11, no. 1, 2021.
[19]
W. Paslawski et al., "Cerebrospinal Fluid Proteins Altered in Corticobasal Degeneration," Movement Disorders, vol. 36, no. 5, s. 1278-1280, 2021.
[20]
K. A. Högelin et al., "Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis," iScience, vol. 24, no. 9, 2021.
[21]
K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.
[22]
N. Kharlamova et al., "False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases," Frontiers in Immunology, vol. 12, 2021.
[23]
M. Rohl et al., "HIV-Exposed Seronegative Sex Workers Express Low T-Cell Activation and an Intact Ectocervical Tissue Microenvironment," Vaccines, vol. 9, no. 3, 2021.
[24]
P. San Segundo-Acosta et al., "Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers," Journal of Proteome Research, vol. 20, no. 11, s. 5115-5130, 2021.
[25]
S. Bergström et al., "Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease," Annals of Clinical and Translational Neurology, vol. 8, no. 7, s. 1456-1470, 2021.
[26]
H. Alkharaan et al., "Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19 : A Complementary Approach to Population Surveys," Journal of Infectious Diseases, vol. 224, no. 3, s. 407-414, 2021.
[27]
S. Hassan et al., "SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden," Journal of Internal Medicine, vol. 290, no. 2, s. 430-436, 2021.
[28]
S. Hober et al., "Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay," Clinical & Translational Immunology (CTI), vol. 10, no. 7, 2021.
[29]
J. Remnestål et al., "Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers," Translational Neurodegeneration, vol. 9, no. 1, 2020.
[30]
I. Markaki et al., "Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson’s Disease," Movement Disorders, 2020.
[31]
D. Just et al., "Exploring autoantibody signatures in brain tissue from patients with severe mental illness," Translational Psychiatry, vol. 10, no. 1, 2020.
[32]
A. Häggmark et al., "A High-throughput Bead-based Affinity Assay Enables Analysis of Genital Protein Signatures in Women At Risk of HIV Infection," Molecular & Cellular Proteomics, vol. 18, no. 3, s. 461-476, 2019.
[33]
A.-L. Lind et al., "CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia," Journal of Pain Research, vol. 12, s. 2875-2889, 2019.
[34]
A. Andersson et al., "Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease," Clinica Chimica Acta, vol. 494, s. 79-93, 2019.
[35]
S. K. Bedri et al., "Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment," PLOS ONE, vol. 14, no. 5, 2019.
[36]
[37]
M. Garranzo-Asensio et al., "Identification of prefrontal cortex protein alterations in Alzheimer's Disease," Oncotarget, vol. 9, no. 13, s. 10847-10867, 2018.
[38]
E. P. Thelin et al., "Protein profiling in serum after traumatic brain injury in rats reveals potential injury markers," Behavioural Brain Research, vol. 340, s. 71-80, 2018.
[39]
A. Zandian et al., "Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis," Translational Psychiatry, vol. 7, 2017.
[40]
A. Zandian et al., "Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy," Journal of Proteome Research, vol. 16, no. 3, s. 1300-1314, 2017.
[41]
P. E. Khoonsari et al., "Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease," PLOS ONE, vol. 11, no. 3, 2016.
[42]
A. Häggmark-Månberg et al., "Autoantibody targets in vaccine-associated narcolepsy," Autoimmunity, vol. 49, no. 6, s. 421-433, 2016.
[43]
J. Remnestål et al., "CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease," PROTEOMICS - Clinical Applications, vol. 10, no. 12, s. 1242-1253, 2016.
[44]
C. Hamsten et al., "Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients," Respiratory Research, vol. 17, 2016.
[45]
C. Fredolini et al., "Immunocapture strategies in translational proteomics," Expert Review of Proteomics, vol. 13, no. 1, s. 83-98, 2016.
[46]
S. Musunuri et al., "Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer's Disease Brain," Journal of Alzheimer's Disease, vol. 54, no. 4, s. 1671-1686, 2016.
[47]
A. Häggmark, J. M. Schwenk och P. Nilsson, "Neuroproteomic profiling of human body fluids," PROTEOMICS - Clinical Applications, vol. 10, no. 4, s. 485-502, 2016.
[48]
C. Hamsten et al., "Protein profiles of CCL5, HPGDS, and NPSR1 in plasma reveal association with childhood asthma," Allergy. European Journal of Allergy and Clinical Immunology, vol. 71, no. 9, s. 1357-1361, 2016.
[49]
E. Sjöstedt et al., "Defining the Human Brain Proteome Using Transcriptomics and Antibody-Based Profiling with a Focus on the Cerebral Cortex," PLOS ONE, vol. 10, no. 6, 2015.
[50]
A. Häggmark et al., "Proteomic Profiling Reveals Autoimmune Targets in Sarcoidosis," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 5, s. 574-583, 2015.
[51]
S. Byström et al., "Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue within Multiple Sclerosis," Journal of Proteome Research, vol. 13, no. 11, s. 4607-4619, 2014.
[52]
F. E. Magraoui et al., "Developing new methods to answer old and new questions in neurodegenerative diseases," Proteomics, vol. 14, no. 11, s. 1308-1310, 2014.
[53]
A. Häggmark et al., "Plasma profiling revelas three proteins associated to amyotrophic lateral sclerosis," Annals of Clinical and Translational Neurology, vol. 1, no. 8, s. 544-553, 2014.
[54]
A. Häggmark et al., "Antibody-based profiling of cerebrospinal fluid within multiple sclerosis," Proteomics, vol. 13, no. 15, s. 2256-2267, 2013.
[55]
B. Ayoglu et al., "Autoantibody profiling in multiple sclerosis using arrays of human protein fragments," Molecular & Cellular Proteomics, vol. 12, no. 9, s. 2657-2672, 2013.
[56]
A. Häggmark et al., "Classification of protein profiles from antibody microarrays using heat and detergent treatment.," New Biotechnology, vol. 29, no. 5, s. 564-570, 2011.
[57]
B. Ayoglu et al., "Systematic antibody and antigen-based proteomic profiling with microarrays," EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. 11, no. 2, s. 219-234, 2011.
Kapitel i böcker
[58]
E. Pin et al., "Array-based profiling of proteins and autoantibody repertoires in CSF," i Cerebrospinal Fluid (CSF) Proteomics, : Humana Press Inc., 2019, s. 303-318.
[59]
A. Häggmark-Månberg, P. Nilsson och J. Schwenk, "Neuroproteomic profiling of cerebrospinal fluid (CSF) by multiplexed affinity arrays," i Neuroproteomics : Methods and Protocols, : Humana Press, 2017, s. 247-254.
Icke refereegranskade
Artiklar
[60]
A. Jernbom Falk et al., "BEYOND NEURORECEPTOR AUTOIMMUNITY : PERIPHERAL AUTOANTIBODY PROFILES ARE ASSOCIATED WITH CLINICAL FEATURES IN PSYCHOTIC DISORDERS," Australian and New Zealand journal of psychiatry (Print), vol. 56, no. 1_SUPPL, s. 90-91, 2022.
[61]
K. O. Schubert et al., "Autoantibody profiles are associated with specific clinical features in psychotic disorders," European psychiatry, vol. 64, 2021.
[62]
G. Edfeldt et al., "Cervicovaginal microbiota affects the human ectocervical epithelial barrier as determined by in situ image analysis and protein profiling," Journal of the International AIDS Society, vol. 24, 2021.
[63]
K. A. Hogelin et al., "Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, s. 348-348, 2021.
[64]
M. Persson et al., "Searching for Novel Autoantibodies with Clinical Relevance in Psychiatric Disorders," Schizophrenia Bulletin, vol. 44, s. S120-S121, 2018.
[65]
D. Just et al., "Towards Molecular Insights Into Psychiatric Disorders Using Affinity Proteomics," Schizophrenia Bulletin, vol. 44, s. S223-S223, 2018.
Avhandlingar
[66]
A. Häggmark, "Neuroproteomic profiling of human body fluids," Doktorsavhandling Stockholm : KTH Royal Institute of Technology, TRITA-BIO-Report, 2015:2, 2015.
Övriga
[67]
S. Mravinacová et al., "Addressing inter-individual variability in CSF levels of brain-derived proteins across neurodegenerative diseases," (Manuskript).
[68]
[69]
S. Bergström et al., "CSF levels of brain-derived proteins correlate with brain ventricular volume in cognitively healthy 70-year-olds," (Manuskript).
[70]
D. Just et al., "Exploring autoantibody signatures in brain tissue lysates from patients with schizophrenia," (Manuskript).
[71]
D. Just et al., "Exploring the autoantibody repertoire in patients with obsessive compulsive disorder," (Manuskript).
[72]
S. Bergström et al., "Multi-cohort protein profiling reveals higher levels of six brain-enriched proteins in Alzheimer’s disease patients," (Manuskript).
[73]
J. Remnestål et al., "Novel CSF protein pattern correlates with biomarker evidence of tau and amyloid β pathology in asymptomatic 70-year-olds," (Manuskript).
[74]
A. Jernbom Falk et al., "Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19," (Manuskript).
Senaste synkning med DiVA:
2024-11-19 00:18:33